Galapagos NV (NASDAQ:GLPG) Q4 2021 Earnings Conference Call February 25, 2022 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer Walid Abi-Saab - Chief Medical Officer Michele Manto - Chief Commercial Officer Conference Call Participants Jason Gerberry - Bank of America Dane Leone - Raymond James Peter Verdult - Citigroup Brian Abrahams - RBC Capital Markets Laura Sutcliffe - UBS Philip ...

Financial Data and Key Metrics Changes - The company reported a cash burn of €377 million for the first nine months leading up to the end of September, with a total cash balance of €4.9 billion at the end of the quarter [34] - The cash burn guidance has been reduced by €50 million, now expected to be in the range of €530 million to €570 million, down from a previous range of €580 million to €620 million [29][30] - Revenue recognition for the quarter was slightly lower due to amendments in the DIVERSITY trial, which affected the accounting under IFRS [35] Business Line Data and Key Metrics Changes - The launch of Jyseleca in Europe is progressing well, with total sales year-to-date reaching €60 million, of which €6 million is booked by Galapagos [23] - The company has taken over the commercialization of filgotinib in Europe, with a reduced royalty rate negotiated with Gilead [14] - The DIVERSITY trial for Crohn's disease is fully recruited, and the company expects to report sales from the launch of Jyseleca soon [11][12] Market Data and Key Metrics Changes - In the EU5 market, the JAK class has a growing market share of 17%, with Jyseleca gaining a 4% share in Germany [24][25] - The company is actively working on reimbursement processes in 14 different countries, with key markets like Germany and Denmark still undergoing procedures [27] Company Strategy and Development Direction - The company is focusing on R&D to discover and develop novel targets while addressing the gap in its pipeline through business development and M&A opportunities [40][42] - The strategic review emphasizes the importance of maintaining a strong R&D focus while also building a commercial infrastructure around filgotinib [41][82] - The company aims to achieve breakeven for the Jyseleca franchise by 2024, with significant cash inflows expected in 2027 and 2028 [32][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the TYK2 program despite recent failures in the market, emphasizing the importance of dosing in ulcerative colitis [48][50] - The company is not considering breaking up its operations, believing that keeping the commercial and R&D aspects together is more beneficial [56] - The outlook remains positive with anticipated approval for ulcerative colitis by the European Commission and ongoing recruitment for the MANGROVE trial [39] Other Important Information - The company is in the process of searching for a new CEO and CSO, with a focus on candidates who have strong R&D backgrounds [13][81] - A contract has been signed with a third-party distributor for Eastern Europe, Portugal, and Greece to promote Jyseleca [28] Q&A Session Summary Question: Thoughts on Bristol's deucra failure in UC and its impact on TYK2 program - Management noted that the failure was surprising and may relate to dosing, emphasizing confidence in their selective TYK2 inhibitor [48][50] Question: Consideration of breaking up the company - Management discussed that keeping the two segments together makes more sense for the company, focusing on bridging the pipeline gap through external acquisitions [56] Question: Evaluation of business development opportunities during CEO search - Management indicated that they are looking for bolt-on transactions in inflammation and fibrosis areas, rather than large transformational deals until a new CEO is appointed [62] Question: Feedback on Jyseleca from physicians - Positive feedback was received regarding Jyseleca's efficacy and safety profile, particularly in Germany, where it is seen as having a differentiating profile compared to peers [100]

Galapagos NV (NASDAQ:GLPG) Q2 2021 Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants Sofie Van Gijsel - IR Onno van de Stolpe - CEO Dr. Walid Abi-Saab - CMO Bart Filius - COO and President Conference Call Participants Brian Abrahams - RBC Capital Markets Laura Sutcliffe - UBS Dane Leone - Raymond James Rosie Turner - Barclays Matthew Harrison - Morgan Stanley Jason Gerberry - Bank of America Lenny Van Steenhuyse - KBC Securities Phil Nadeau - Cowen Wimal Kapadia - Bernstein Operator Go ...

Galapagos NV (NASDAQ:GLPG) Q1 2021 Earnings Conference Call May 7, 2021 8:00 AM ET Company Participants Elizabeth Goodwin - VP of IR Onno Van De Stolpe - Co-Founder & CEO Bart Filius - President & COO Walid Abi-Saab - Chief Medical Officer Piet Wigerinck - Chief Scientific Officer Michele Manto - Chief Commercial Officer Conference Call Participants Peter Welford - Jefferies Jason Gerberry - Bank of America Merrill Lynch Graig Suvannavejh - Goldman Sachs Laerke Engkilde - JPMorgan Wimal Kapadia - Bernstein ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ OR ☐ SHELL COMPANY REPORT PURSUANT TO ...

| --- | --- | |-----------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | We discover. We dare. We care. | | | Investor Relations slides \| March 2021 | | | Gal Pioneering f | | Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our R&D and clinical pipeline, our expectations regarding commercial sales of Jyseleca, the global R&D collaboration with Gilead, the amendment of our arrang ...

Galapagos NV (NASDAQ:GLPG) Q4 2020 Earnings Conference Call February 19, 2021 8:00 AM ET Company Participants Elizabeth Goodwin - Vice President, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid Abi-Saab - Chief Medical Officer Piet Wigerinck - Chief Scientific Officer Michele Manto - Chief Commercial Officer Conference Call Participants Laura Sutcliffe - UBS AG Peter Welford - Jefferies Brian Abrahams - RBC Capital Markets ...

Galapagos NV (NASDAQ:GLPG) Q3 2020 Results Conference Call November 6, 2020 8:00 AM ET Company Participants | --- | |-----------------------------------------------------| | | | Elizabeth Goodwin - Investor Relations | | Onno van de Stolpe - Chief Executive Officer | | Andre Hoekema - Chief Business Officer | | Bart Filius - Chief Operating and Financial Officer | | Walid Abi-Saab - Chief Medical Officer | | Piet Wigerinck - Chief Scientific Officer | | Michele Manto - Chief Commercial Officer | | Conferenc ...

| --- | --- | |-------------------------------------------------------------|-------| | | | | Q3 2020 results | | | webcast | | | Onno van de Stolpe, CEO Piet Wigerinck, CSO 6 November 2020 | | | | | Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the statements regarding the global R&D collaboration with Gilead, statements relating to interactions with regulatory authorities, the timing or likeliho ...

Galápagos We discover We dare We care Investor Relations slides | August 2020 1 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the statements regarding the global R&D collaboration with Gilead, the amount and timing of potential future milestone, opt-in and/or royalty payments by Gilead, statements relating to interactions with regulatory authorities, the potential approval process for filgotinib a ...